<DOC>
	<DOCNO>NCT00116610</DOCNO>
	<brief_summary>This Phase II research study design patient small cell lung cancer ( SCLC ) longer respond treatment . Patients receive picoplatin , new platinum-based agent currently investigation , 21-day cycle .</brief_summary>
	<brief_title>Picoplatin Second-Line Therapy Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>Platinum drug work bind DNA prevent rapid cell division tumor . However , many tumor demonstrate resistance platinum drug . Results preclinical study indicate picoplatin ( previously call AMD473 ZD0473 ) may able overcome partially overcome platinum resistance . More 500 patient receive picoplatin previous Phase I Phase II clinical trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Main inclusion criterion : 1 . Diagnosis small cell lung cancer . 2 . Patients must one prior chemotherapy regimen must include either cisplatin carboplatin . [ Additional eligibility criterion apply . ] Prior radiotherapy include &gt; 30 % bone marrow ( i.e. , whole pelvis half spine ) . Significant chronic recent acute gastrointestinal disorder diarrhea major symptom . Significant heart disease . Uncontrolled , untreated , unstable , symptomatic brain tumor central nervous system disease . Grade 2+ peripheral neuropathy ( condition cause damage nerve peripheral nervous system ) . [ Additional exclusion criterion apply . ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>resistant</keyword>
	<keyword>refractory</keyword>
	<keyword>platinum</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>second-line</keyword>
	<keyword>relapse</keyword>
	<keyword>sensitive</keyword>
</DOC>